News
NVAX
8.94
+6.18%
0.52
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
Barchart · 2d ago
Novavax Inc. Stock Rises 6.2%, Outperforms Peers
Dow Jones · 2d ago
HHS seeking public input on vaccine recommendation categories
Seeking Alpha · 2d ago
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
Barchart · 2d ago
3 Unprofitable Stocks Walking a Fine Line
Barchart · 3d ago
Novavax Inc. Stock Slips 4.2%, Underperforms Peers
Dow Jones · 3d ago
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
Barron‘s · 3d ago
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
Benzinga · 3d ago
Novavax (NVAX) Is Up 10.4% After Steep Q2 Revenue Drop And Swing To Net Loss – Has The Bull Case Changed?
Simply Wall St · 4d ago
Novavax Inc. Stock Rallies 10.8%, Outperforms Peers
Dow Jones · 4d ago
Notable Wednesday Option Activity: NVAX, TLN, BULL
NASDAQ · 4d ago
BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
Barron‘s · 4d ago
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
Seeking Alpha · 4d ago
New CDC director says vaccines are 'safe and effective'
Seeking Alpha · 4d ago
Novavax call volume above normal and directionally bullish
TipRanks · 4d ago
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Benzinga · 4d ago
Moderna surges on trial win for cancer shot; William Blair upgrades
Seeking Alpha · 4d ago
Unusually active option classes on open August 19th
TipRanks · 4d ago
Novavax (NVAX) Shares Skyrocket, What You Need To Know
Barchart · 4d ago
What Is Drawing Fresh Attention To Novavax (NVAX)?
Simply Wall St · 6d ago
More
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax Inc through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.